Analytical method for fluazifop-p-butyl and its acid degradate (R156172) in soil

Reports:	ECM: EPA MRID No.: 4959240 Fluazifop-P-Butyl – Analytical M Determination of Fluazifop-P-B (R156172) in Soil – Analytical M No.: TK0062679. Report prepar Crop Protection, LLC., Greensbe issued March 12, 2015.	Method for E utyl (R15487 Method. Repo ed, sponsored	nantiomeric Ratio and Residue 5; PP5) and its Acid Degradate ort No.: GRM044.05A. Task I and submitted by Syngenta
Document No.: Guideline:	ILV: EPA MRID No. 49800201 Independent Laboratory Validat (GRM044.05A) for Enantiomeri Fluazifop-P-Butyl (R154875; PF – Final ILV Report. Report No.: 1187. Task No.: TK0278222. Re Solutions Corp., Princeton, New Syngenta Crop Protection, LLC. Final report issued December 11 MRIDs 49592401 & 49800201 850.6100	ion of Ameno ic Ratio and F P5) and its Ac PASC-REP- eport prepared Jersey, spon , Greensboro	ded Analytical Method Residue Determination of cid Degradate (R156172) in Soil 0656. PASC Project No.: 141- d by Primera Analytical sored and submitted by
Statements:	ECM: The study was not conduc	cted in compl	iance with USEPA FIFRA or
	OECD Good Laboratory Practic 49592401). Signed and dated No were provided (pp. 2-3). A certif Assurance statement were not in previous method version was inc	Data Confid fication of autocluded. A sig	lentiality and GLP statements thenticity and Quality
Classification:	ILV: The study was conducted is standards (40 CFR Part 160; p. 3 Data Confidentiality, GLP and ((pp. 2-4). An authenticity statem This analytical method is classif number of samples was insuffici- chromatograms were provided for baseline noise and non-uniform chromatograms for the S enantic	3 of MRID 49 Quality Assur- nent was not i ied as Unacc lent for all and or the test ma integration w	2800201). Signed and dated No ance statements were provided ncluded. eptable . In the ECM, the alyses, and no representative strix. In the ILV, some minor as noted in the representative
PC Code:	122809		RICHARD Digitally signed by RICHARD SHAMBLEN
Final EPA	Richard Shamblen,	Signature: S	
Reviewer:	Biologist Lisa Muto,	Date:	June 26, 2019
CDM/CSS	Environmental Scientist	Signature:	Lesa Muto
CDM/CSS- Dynamac JV	Kathlaan Faraysan Dh D	Date:	1/10/17
Reviewers:	Kathleen Ferguson, Ph.D., Environmental Scientist	Signature:	1/10/17 Karalun P. Jerguson
		Date:	1/10/17

This Data Evaluation Record may have been altered by the Environmental Fate and Effects Division subsequent to signing by CDM/CSS-Dynamac JV personnel.

Page numbers cited in ILV MRID 49800201 refer to those reported in the lower right-hand corner of the document.

Executive Summary

This analytical method, Syngenta Method GRM044.05A, is designed for the quantitative determination of the S and R enantiomers of fluazifop-p-butyl and fluazifop-p-acid (fluazifop) in soil at the LOQ of 1.0 µg/kg (1.0 ppb) using LC/MS/MS. The LOQ is less than the lowest toxicological level of concern in soil. The analytical method provided an optional solid phase extraction (SPE) procedure for difficult soil matrices. The optional SPE procedure was not performed by the ILV; the ECM did not specify if the optional SPE extraction was performed. In the ECM, the method was validated using characterized sand soil; however, an insufficient number of samples was prepared for all analyses (n = 3). Additionally, no representative chromatograms were provided for the test matrix. Two ion transitions were reported in the method, but only the primary ion transitions were monitored. A confirmatory method is not usually required when the primary analytical method is LC/MS/MS or GC/MS/MS. An updated ECM should be submitted with acceptable chromatographic support. The ILV validated the method for all four analytes using characterized clay loam and sandy loam soils after one trial with insignificant modifications to the analytical method. Two ion transitions were monitored in the ILV. For fluazifop, some minor baseline noise and non-uniform integration was noted for the S enantiomer at the LOQ.

	MRI	(D						Limit of
Analyte(s) by Pesticide	Environmental Chemistry Method	Independent Laboratory Validation	EPA Review	Matrix	Method Date (dd/mm/yyyy)	Registrant	Analysis	Quantitation (LOQ)
S enantiomer of Fluazifop- P-Butyl (R159618) R enantiomer of Fluazifop- P-Butyl (R154875; PP5) S enantiomer of Fluazifop- P-Acid ¹ (R159697) R enantiomer	49592401 ^{2,3}	49800201 ⁴		Soil	12/03/2015	Syngenta Crop Protection, LLC	LC/MS/MS	1.0 μg/kg; 0.001 mg/kg; 1.0 ppb
of Fluazifop- P-Acid ¹ (R156172)								

Table 1. Analytical Method Summary

1 Referred to as Fluazifop in DER.

2 In the ECM, sand soil (90% sand, 8% silt, 2% clay; pH 6.3 in 0.01M CaCl₂; 0.55% organic carbon) was characterized in Syngenta Study TK0015266 Final Report (Table 13), August 2, 2013 (Terrestrial field dissipation study; Table 1, p. 30 of MRID 49592401). USDA soil texture classification was not specified. The source was not specified.

3 ECM recovery data was obtained from Syngenta Study TK0015266, Analytical Phase Report Amendment 2 (November 26, 2014; Tables 2-3, pp. 31-32 of MRID 49592401).

4 In the ILV, clay loam soil (21% sand, 42% silt, 37% clay; pH 7.6 in 0.01M CaCl₂; % organic carbon not reported) was obtained from Underwood farm, 0-6" depth (Table 1, p. 33 of MRID 49800201). The sandy loam soil (55% sand, 28% silt, 17% clay; pH 7.3 in 0.01M CaCl₂; % organic carbon not reported) and obtained from Madera, California, 1-15-13, 0-6" depth. Both soils were characterized in Syngenta Study TK0002309 by Agvise Laboratories, Northwood, North Dakota; USDA soil texture classification was not specified. The sources were not further specified.

I. Principle of the Method

Soil samples (20 g) were weighed into 50-mL polypropylene centrifuge tubes and fortified, if necessary. After 5 minutes of equilibration of the fortification solution, the soil was extracted twice with acetonitrile:10 mM ammonium acetate buffer at pH 5 (50:50, v:v; 30 mL first extraction, 20 mL second extraction) by shaking at room temperature for 20 minutes (speed not specified); tubes should be placed in the horizontal position during shaking (pp. 16-17; Appendices 1-4, pp. 102-106 of MRID 49592401). After centrifugation at *ca*. 5000 rpm for *ca*. 10 minutes, the supernatant was transferred to a clean 50-mL centrifuge tube. The method noted that it was acceptable for the supernatant of some soils, especially those with a high clay content, may remain cloudy after centrifugation. The volume of the combined extracts was adjusted to 50 mL with 10 mM ammonium acetate buffer at pH 5. An aliquot (1 mL) was filtered with a 1-mL glass syringe containing a PTFE syringe membrane filter (13 mm; 0.2 μ m). A 500- μ L aliquot of the filtered extract was diluted with 500 μ L of 10 mM ammonium acetate buffer at pH 5 (2x dilution) prior to analysis via LC/MS/MS. Further dilution with acetonitrile:10 mM ammonium

acetate buffer at pH 5 (50:50, v:v) may be necessary when sample contain more than 1000 ppb of residues or interferences are detected.

An optional solid phase extraction (SPE) clean-up was provided in case insufficient instrument sensitivity or significant matrix effects interfered with results (p. 17 of MRID 49592401). The Waters Oasis® MAX SPE cartridge (150 mg, 6-mL) was preconditioned sequentially with methanol (3 mL x 2), acetonitrile (3 mL x 2), methanol (3 mL x 2), 0.01% NH₄OH in water (3 mL x 2) and water (3 mL x 2). An aliquot (5 mL) of the final combined extracts (from above) were diluted with 5.0 mL of 10 mM ammonium acetate buffer at pH 5 in a 15-mL polypropylene centrifuge tube. The diluted soil extract was applied to the column, portion-wise with a slight positive pressure or vacuum (flow less than 20 drops/minute). The polypropylene centrifuge tube was rinsed with 2.0 mL of 0.1% formic acid in methanol:ultra-pure water (20:80, v:v) and then ultra-pure water (3 mL x 2). Each of the rinsates were used to wash the SPE column. The analytes were collected with acidified (1% formic acid) acetonitrile:acetone (25:75, v:v; 2 mL x 3). The eluate was collected into a clean 15-mL polypropylene centrifuge tube. The eluate was evaporated to dryness under a gentle stream of nitrogen ro air at a bath temperature of ca. 40C. Acetonitrile (0.3 mL) was added to the centrifuge tube and vortexed. The final volume was adjusted to 1 mL with 10 mM ammonium acetate buffer at pH 5 or an appropriate volume of acetonitrile:10 mM ammonium acetate buffer at pH 5 (30:70, v:v). An aliquot of the final sample was transferred to an autosampler vial for analysis by LC/MS/MS. Further dilution with acetonitrile:10 mM ammonium acetate buffer at pH 5 (30:70, v:v) may be necessary.

Samples were analyzed for fluazifop-P-butyl (S enantiomer, R159618; R enantiomer, PP5) and fluazifop (S enantiomer, R159697; R enantiomer, R156172) by Surveyor Plus LC system (Chiralpak AS-RH, 150 x 4.6 mm, 5.0 μ m column; column temperature 25°C) with a column filter (ColumnSaver) using a gradient mobile phase of (A) 0.1% formic acid in Optima grade water, (B) HPLC grade 2-propanol and (C) 0.1% formic acid in HPLC grade acetonitrile [time ratio A:B:C; 0.0-3.0 min. 50:5:45, 4.0-12.0 min. 35:5:60, 12.1-13.0 min. 50:5:45] coupled with a Thermo Electron TSQ Quantum Ultra mass spectrometer with HESI-II probe (300°C) in positive ion or negative ion mode (Multiple Reaction Monitoring mode, MRM; pp. 19-22). Analytes were identified with two transitions, primary and confirmation ion transitions. Positive mode was employed for fluazifop-P-butyl (R and S enantiomers) with transitions of 384.10 \rightarrow 282.10 and 384.14 \rightarrow 328.10. Negative mode was employed for fluazifop (R and S enantiomers) with transitions of 326.10 \rightarrow 254.10 and 326.10 \rightarrow 226.10. Injection volumes were 50 μ L. Retention times were 10.7 minutes for fluazifop-P-butyl (R and S enantiomers), 5.8 minutes for fluazifop (S enantiomer) and 6.5 minutes for fluazifop (R enantiomer).

In the ILV, the ECM was performed as written, except that mobile phase B was added to solvents A and C at 5% and eliminated (pp. 23-26 of MRID 49800201). The SPE extraction was not performed. The analytical instrument was a Waters Acquity UPLC system coupled to an Applied Biosystems Sciex API 6500 triple quadrupole mass spectrometer. The mobile phase was adjusted to (A) 0.1% formic acid in water with 5% 2-propanol and (B) 0.1% formic acid in acetonitrile with 5% 2-propanol [time ratio A:B; 0.0-3.0 min. 52.6:47.4, 4.0-12.0 min. 36.8:63.2, 12.1-13.0 min. 52.6:47.4. Approximate retention times were *ca*. 9.82 minutes for fluazifop-P-butyl (S enantiomer), 10.31 minutes for fluazifop-P-butyl (R enantiomer), 5.70 minutes for fluazifop (S enantiomer) and 6.36 minutes for fluazifop (R enantiomer. The ILV study author

noted that the S enantiomer was not supplied by the sponsor, so the retention time of the S enantiomer was established using the racemic mixture (p. 19). Monitored transitions basically matched those reported in the ECM (p. 26). No other modifications of the ECM were reported.

The Limit of Quantification (LOQ) for fluazifop-P-butyl and fluazifop was reported as 1.0 μ g/kg (1.0 ppb; 0.001 mg/kg) in the ECM and the ILV (pp. 11, 26 of MRID 49592401; pp. 23, 27 of MRID 49800201). The Limit of Detection (LOD) for the individual enantiomers was 0.05 ng/mL when using a 50 μ L injection volume (2.5 pg injected on column) in the ECM. The LOD was not specifically reported in the ILV, but the lowest calibration standard was the 0.05 ng/mL individual enantiomer concentration level.

II. Recovery Findings

ECM (MRID 49592401): Mean recoveries and relative standard deviations (RSDs) were within guideline requirements (mean 70-120%; RSD \leq 20%) for analysis of S and R enantiomers of fluazifop-P-butyl at fortification levels of 1.0 µg/kg (LOQ), 10 µg/kg (10x LOQ) and 100 µg/kg (100x LOQ) and S and R enantiomers of fluazifop at fortification levels of 1.0 µg/kg (LOQ), 10 µg/kg (10x LOQ) and 500 µg/kg (500x LOQ) in sand soil (p. 26; Tables 2-3, pp. 31-32; DER Attachment 2). ECM recovery data was obtained from Syngenta Study TK0015266, Analytical Phase Report Amendment 2 (November 26, 2014; terrestrial field dissipation study); it was not specified if the optional SPE extraction was performed in that study. The number of samples was insufficient for all analyses (n = 3). Two ion transitions were reported in the method, but only the primary ion transitions were monitored. A confirmatory method is not usually required when the primary analytical method is LC/MS/MS or GC/MS/MS. Standard deviations were reviewercalculated using the individual recovery values reported in the study report since standard deviations were not provided by the study author (DER Attachment 2). The means and RSDs for fluazifop (S) at 10 and 500 µg/kg were reviewer-calculated since the values provided in the study report were erroneous (for 10 µg/kg: mean 102% and RSD 13%; for 500 µg/kg: mean 107% and RSD 4.6%; Table 3, p. 32). The sand soil (90% sand, 8% silt, 2% clay; pH 6.3 in 0.01M CaCl₂; 0.55% organic carbon) was characterized in Syngenta Study TK0015266 Final Report (Table 13), August 2, 2013 (Table 1, p. 30). USDA soil texture classification was not specified. The source was not specified.

ILV (MRID 49800201): Mean recoveries and RSDs were within guideline requirements for analysis of S and R enantiomers of fluazifop-P-butyl and fluazifop in clay loam and sandy loam soils at fortification levels of 0.001 mg/kg (LOQ) and 0.01 mg/kg (10x LOQ; Tables 3-10, pp. 35-42). All analytes were identified using two ion transitions; performance data (recovery results) from primary and confirmatory analyses were comparable. The clay loam soil (21% sand, 42% silt, 37% clay; pH 7.6 in 0.01M CaCl₂; % organic carbon not reported) was obtained from Underwood farm, 0-6" depth (Table 1, p. 33). The sandy loam soil (55% sand, 28% silt, 17% clay; pH 7.3 in 0.01M CaCl₂; % organic carbon not reported) and obtained from Madera, California, 1-15-13, 0-6" depth. Both soils were characterized in Syngenta Study TK0002309 by Agvise Laboratories, Northwood, North Dakota; USDA soil texture classification was not specified. The sources were not further specified. The method was validated for all analytes in

both matrices after one trial with insignificant modifications to the analytical method (pp. 23-24, 27).

Fluazifop-p-butyl (R enantiomer) Fluazifop-p-butyl (S enantiomer) Fluazifop (R enantiomer)	Level (μg/kg) 1.0 (LOQ) 10 100 1.0 (LOQ) 10 10	of Tests 3 3 3 3	85-89 71-85	Sand Soil ³ mary Transition 86	Deviation (%) ²	Deviation (%)
Fluazifop-p-butyl (R enantiomer) Fluazifop-p-butyl (S enantiomer) Fluazifop (R enantiomer)	10 100 1.0 (LOQ)	3 3	85-89 71-85	nary Transition 86	2	
Fluazifop-p-butyl (R enantiomer) Fluazifop-p-butyl (S enantiomer) Fluazifop (R enantiomer)	10 100 1.0 (LOQ)	3 3	85-89 71-85	86	2	
Fluazifop-p-butyl (R enantiomer) Fluazifop-p-butyl (S enantiomer) Fluazifop (R enantiomer)	10 100 1.0 (LOQ)	3 3	71-85		2	r
(R enantiomer) Fluazifop-p-butyl (S enantiomer) Fluazifop (R enantiomer)	100 1.0 (LOQ)	3		76		2.7
Fluazifop-p-butyl (S enantiomer)	1.0 (LOQ)		00 101	76	8	10
Fluazifop-p-butyl (S enantiomer)			90-101	95	6	5.9
(S enantiomer)	10	3	88-91	90	2	1.7
Fluazifop (R enantiomer)		3	71-85	76	8	11
Fluazifop (R enantiomer)	100	3	90-100	94	6	5.9
(R enantiomer)	1.0 (LOQ)	3	77-87	81	5	6.3
	10	3	87-105	93	10	11
Fluazifon	500	3	90-97	93	4	3.9
Fluazifon	1.0 (LOQ)	3	98-107	102	5	4.5
	10	3	94-117	104 ⁴	12	114
(S enantiomer)	500	3	107-110	109 ⁴	2	14
			Confi	matory Transitic	n	
	1.0 (LOQ)	3				
Fluazifop-p-butyl	10	3				
(R enantiomer)	100	3				
	1.0 (LOQ)	3				
Fluazifop-p-butyl	10	3				
(S enantiomer)	100	3				
	1.0 (LOQ)	3		No	ot reported	
Fluazifop	10	3				
(R enantiomer)	500	3				
	1.0 (LOQ)	3				
Fluazifop	10	3				
(S enantiomer)		3				

Table 2 Initial Validation	Mathad Decovarias f	n Fluorifon n hutul	and Elugrifon in Sail
Table 2. Initial Validation	i methoù Kecoveries i	n riuaziiop-p-butyi	and Fluazhop in Son

Data (uncorrected recovery results, pp. 22-23) were obtained from Tables 2-3, pp. 31-32 of MRID 49592401 and DER Attachment 2.

1 The ECM recovery data was obtained from Syngenta Study TK0015266, Analytical Phase Report Amendment 2 (November 26, 2014; terrestrial field dissipation study); it was not specified if the optional SPE extraction was performed in that study (p. 26; Tables 2-3, pp. 31-32).

2 Standard deviations were reviewer-calculated using the individual recovery values reported in the study report since standard deviations were not provided by the study author (DER Attachment 2).

3 The sand soil (90% sand, 8% silt, 2% clay; pH 6.3 in 0.01M CaCl₂; 0.55% organic carbon) was characterized in Syngenta Study TK0015266 Final Report (Table 13), August 2, 2013 (Table 1, p. 30). USDA soil texture classification was not specified. The source was not specified.

4 The means and RSDs for fluazifop (S) at 10 and 500 μg/kg were reviewer-calculated since the values provided in the study report were erroneous (for 10 μg/kg: mean 102% and RSD 13%; for 500 μg/kg: mean 107% and RSD 4.6%; Table 3, p. 32).

Analyte	Fortification Level (mg/kg)	Number of Tests	Recovery Range (%)	Mean Recovery (%)	Standard Deviation (%)	Relative Standard Deviation (%)
			Cl	ay Loam Soil ¹		
			Pri	nary Transition		
Fluazifop-p-butyl	0.001 (LOQ)	5	83-90	87	2	3
(S enantiomer)	0.01	5	81-88	84	3	3
Fluazifop-p-butyl	0.001 (LOQ)	5	84-92	87	3	4
(R enantiomer)	0.01	5	80-88	82	3	4
Fluazifop	0.001 (LOQ)	5	88-97	92	3	4
(S enantiomer)	0.01	5	85-90	87	2	2
Fluazifop	0.001 (LOQ)	5	93-98	95	2	2
(R enantiomer)	0.01	5	88-92	89	1	1
			Confi	matory Transitio	n	
Fluazifop-p-butyl	0.001 (LOQ)	5	83-89	86	2	3
(S enantiomer)	0.01	5	81-88	83	3	4
Fluazifop-p-butyl	0.001 (LOQ)	5	84-93	87	3	4
(R enantiomer)	0.01	5	79-87	82	3	4
Fluazifop	0.001 (LOQ)	5	87-93	90	3	3
(S enantiomer)	0.01	5	84-89	86	2	2
Fluazifop	0.001 (LOQ)	5	97-106	101	4	4
(R enantiomer)	0.01	5	87-90	88	1	1
			Sar	ndy Loam Soil ¹		•
			Pri	mary Transition		
Fluazifop-p-butyl	0.001 (LOQ)	5	98-101	100	1	1
(S enantiomer)	0.01	5	90-95	92	2	2
Fluazifop-p-butyl	0.001 (LOQ)	5	98-101	100	2	2
(R enantiomer)	0.01	5	92-97	94	2	2
Fluazifop	0.001 (LOQ)	5	93-100	97	3	3
(S enantiomer)	0.01	5	90-95	91	2	2
Fluazifop	0.001 (LOQ)	5	94-105	100	4	4
(R enantiomer)	0.01	5	90-95	92	2	2
			Confi	matory Transitio	n	
Fluazifop-p-butyl	0.001 (LOQ)	5	99-101	100	1	1
(S enantiomer)	0.01	5	90-94	91	2	2
Fluazifop-p-butyl	0.001 (LOQ)	5	96-101	99	2	2
(R enantiomer)	0.01	5	92-97	94	2	2
Fluazifop	0.001 (LOQ)	5	90-103	97	4	5
(S enantiomer)	0.01	5	89-91	91	2	2
Fluazifop	0.001 (LOQ)	5	84-105	94	8	8
(R enantiomer)	0.01	5	87-93	90	2	3

Table 3. Independent Validation Method Recoveries for Fluazifop-p-butyl and Fluazifop inSoil

Data (uncorrected recovery results, Appendix 1, pp. 142-143) were obtained from Tables 3-10, pp. 35-42 of MRID 49800201.

1 The clay loam soil (21% sand, 42% silt, 37% clay; pH 7.6 in 0.01M CaCl₂; % organic carbon not reported) was obtained from Underwood farm, 0-6" depth (Table 1, p. 33). The sandy loam soil (55% sand, 28% silt, 17% clay; pH 7.3 in 0.01M CaCl₂; % organic carbon not reported) and obtained from Madera, California, 1-15-13, 0-6" depth. Both soils were characterized in Syngenta Study TK0002309 by Agvise Laboratories, Northwood, North Dakota; USDA soil texture classification was not specified. The sources were not further specified.

III. Method Characteristics

The LOQ for fluazifop-P-butyl and fluazifop was reported as 1.0 μ g/kg (1.0 ppb; 0.001 mg/kg) in the ECM and the ILV (pp. 11, 26 of MRID 49592401; pp. 23, 27 of MRID 49800201). In the ECM, the LOQ was defined as the lowest analyte concentration which was demonstrated to have acceptable mean recovery (70 to 120%) and precision (relative standard deviation of 20%). The ECM also stated that the response of the LOQ analyte peak should be no lower than four times the mean amplitude of the background noise in an untreated sample at the corresponding retention time. No justification for the LOQ was provided in the ILV. The LOD for the individual enantiomers was 0.05 ng/mL when using a 50 μ L injection volume (2.5 pg injected on column) in the ECM. In the ECM, the LOD was defined as the lowest analyte concentration detectable above the mean amplitude of the background noise in an untreated sample at the corresponding retention time. The ECM also stated that an estimate of the LOD can be taken as three times background noise. The LOD was not specifically reported in the ILV, but the lowest calibration standard was the 0.05 ng/mL individual enantiomer concentration level. No justification for the LOD was provided in the ILV.

Analyte		Fluazifop-p-butyl	Fluazifop		
Limit of Quantitation	ECM	1.0	ug/kg		
(LOQ)	ILV	(0.001 mg/kg; 1.0 ppb)			
Limit of Detection	ECM	0.05 ng/mL when using	a 50 µL injection volume		
(LOD)		(2.5 pg inject	ed on column)		
	ILV	Not reported			
		$r^2 = 0.9985 (S,Q)$	$r^2 = 0.9997$ (S,Q)		
	ECM	$r^2 = 0.9976$ (S,C)	$r^2 = 0.9994$ (S,C)		
	ECIVI	$r^2 = 0.9986 (R,Q)$	$r^2 = 0.9996 (R,Q)$		
T '		$r^2 = 0.9976 (R,C)$	$r^2 = 0.9991 (R,C)$		
Linearity (calibration curve r^2 and		$r^2 = 0.9974$ (S,Q)	$r^2 = 0.9996 (S,Q)$		
	ILV^1	$r^2 = 0.9976$ (S,C)	$r^2 = 0.9996 (S,C)$		
concentration range)	IL V	$r^2 = 0.9976 (R,Q)$	$r^2 = 0.9996 (R,Q)$		
		$r^2 = 0.9982 (R,C)$	$r^2 = 0.9986 (R,C)$		
	Concentration	(0.05-10 µg/L)			
	Range				
Repeatable		Insufficient samples	s were prepared (n= 3)		
	ECM ^{2,3,4}	Yes at LOQ, 10×LOQ and	Yes at LOQ, 10×LOQ and		
		100×LOQ	500×LOQ		
	ILV ^{5,6}	Yes at LOQ and 10×LOQ			
Reproducible		Yes at LOQ and 10×LOQ			
Specific	ECM	Could not be	e determined.		
		Chromatograms were not p	provided for the test matrix. ⁷		
		Matrix interferences repo	orted as $<30\%$ of the LOQ.		
	ILV		Yes, matrix interferences were <1%		
			for the primary transition and <10%		
		Yes, no matrix interferences were	for the confirmatory transition.		
		observed.	Some minor baseline noise and		
			non-uniform integration was noted		
			for the S enantiomer at the LOQ. ⁸		

Table 4. Method Characteristics

Data were obtained from pp. 11, 26-27; Tables 2-3, pp. 31-32 (recovery data); Figures 8-18, pp. 46-87 (chromatograms); Figures 19-26, pp. 89-96 (calibration curves) of MRID 49592401; pp. 23, 27; Tables 3-10, pp. 35-42 (recovery data); Figures 9-134, pp. 48-110 (calibration curves and chromatograms) of MRID 49800201 and DER Attachment 2. S = S enantiomer; R = R enantiomer; Q = primary ion transition; C = confirmatory ion transition.

- 1 For the ILV, correlation coefficients for all analytes were reviewer-calculated from r values provided in the study report (Figures 25-26, p. 56; Figures 57-58, p. 72; Figures 89-90, p. 88; Figures 121-122, p. 104 of MRID 49800201; DER Attachment 2).
- 2 In the ECM, sand soil (90% sand, 8% silt, 2% clay; pH 6.3 in 0.01M CaCl₂; 0.55% organic carbon) was characterized in Syngenta Study TK0015266 Final Report (Table 13), August 2, 2013 (Table 1, p. 30 of MRID 49592401). USDA soil texture classification was not specified. The source was not specified.
- 3 In the ECM. two ion transitions were reported in the method, but only the primary ion transition was monitored. A confirmatory method is not usually required when the primary analytical method is LC/MS/MS or GC/MS/MS.
- 4 ECM recovery data was obtained from Syngenta Study TK0015266, Analytical Phase Report Amendment 2 (November 26, 2014; Tables 2-3, pp. 31-32 of MRID 49592401).
- 5 In the ILV, clay loam soil (21% sand, 42% silt, 37% clay; pH 7.6 in 0.01M CaCl₂; % organic carbon not reported) was obtained from Underwood farm, 0-6" depth (Table 1, p. 33 of MRID 49800201). The sandy loam soil (55% sand, 28% silt, 17% clay; pH 7.3 in 0.01M CaCl₂; % organic carbon not reported) and obtained from Madera, California, 1-15-13, 0-6" depth. Both soils were characterized in Syngenta Study TK0002309 by Agvise Laboratories, Northwood, North Dakota; USDA soil texture classification was not specified.
- 6 The ILV validated the method for all analytes in both matrices after one trial with insignificant modifications to the analytical method (pp. 23-24, 27 of MRID 49800201).
- 7 Chromatograms were only provided for loam and sandy loam soil matrices; neither of which was a test matrix.
- 8 Based on Figures 93-94, p. 90 and Figures 99-100, p. 93 of MRID 49800201.

IV. Method Deficiencies and Reviewer's Comments

- The ILV MRID 49800201 was performed based on an updated version of ECM MRID 49592401 entitled "Fluazifop-P-Butyl: Fluazifop-P-Butyl – Analytical Method for Enantiomeric Ratio and Residue Determination of Fluazifop-P-Butyl (R154875; PP5) and its Acid Degradate (R156172) in Soil – Amended Analytical Method" (June 25, 2015; Appendix 1, pp. 121-226 of MRID 49800201). The only change to the original method was the corrections of a typographical error in the title of several figures: S-Fluazifop-Butyl was changed to R-Fluazifop-Butyl (Appendix 1, p. 124, 131). The entire Amended ECM was provided in Appendix 1 of the ILV. This Amended ECM was reviewed and determined to be the same as MRID 49592401, except for the typographical error changes.
- 2. In the ECM, the number of samples was insufficient for all analyses (n = 3; Tables 2-3, pp. 31-32 of MRID 49592401). A validation sample set should consist of, at a minimum, a reagent blank, two unspiked matrix control samples, five matrix control samples spike at the LOQ, and five matrix control samples spiked at 10×LOQ for each analyte and matrix.

- 3. In the ECM, chromatograms were not provided to confirm the specificity of the method (Figures 8-18, pp. 46-87 of MRID 49800201). Chromatograms were not provided for the test matrix, sand soil; chromatograms were only provided for loam and sandy loam soil matrices. The representative chromatograms were noted as from "Method Development" (p. 39). An updated ECM should be submitted with acceptable chromatographic support. Representative chromatograms from the test matrix should be provided for review of method specificity.
- 4. In the ILV, the reviewer noted that some minor baseline noise (<30% of the LOQ) and non-uniform integration was noted in the representative chromatograms for the S enantiomer of fluazifop at the LOQ (Figures 93-94, p. 90; Figures 99-100, p. 93 of MRID 49800201).
- 5. The reviewer noted that the sand soil was characterized in Table 1 which was titled "Charaterisation Data for Soil Samples Used in TK0015266 Method Trial" (Table 1, p. 30 of MRID 49592401). Syngenta TK0015266 was identified as a terrestrial field dissipation study (p. 26). Additionally, the reviewer noted that the study author stated that "the method recovery data obtained from TK0015266 [was] based on a multi point approach" (p. 26).
- 6. The estimations of LOQ and LOD in ECM were not based on scientifically acceptable procedures as defined in 40 CFR Part 136 ILV (pp. 11, 26 of MRID 49592401; pp. 23, 27 of MRID 49800201). In the ECM, the LOQ was defined as the lowest analyte concentration which was demonstrated to have acceptable mean recovery (70 to 120%) and precision (relative standard deviation of 20%). The ECM also stated that the response of the LOQ analyte peak should be no lower than four times the mean amplitude of the background noise in an untreated sample at the corresponding retention time. No justification for the LOQ was provided in the ILV. The LOD for the individual enantiomers was 0.05 ng/mL when using a 50 µL injection volume (2.5 pg injected on column) in the ECM. In the ECM, the LOD was defined as the lowest analyte concentration detectable above the mean amplitude of the background noise in an untreated sample at the corresponding retention time. The ECM also stated that an estimate of the LOD can be taken as three times background noise. The LOD was not specifically reported in the ILV, but the lowest calibration standard was the 0.05 ng/mL individual enantiomer concentration level. No calculations were reported to justify the LOQ and LOD for the method.
- 7. Communications between the ILV and study monitor were summarized as 1) clarification/approval of the protocol and method, 2) acquisition of analytical standard and control sample, and 3) acquisition of the revised method with changes to the test procedures (p. 30 of MRID 49800201). The list of email communications was provided in Appendix 6, pp. 241-247.
- 8. In the ECM and ILV, no significant matrix effects (>20%) were observed for soils (p. 27; Table 4, p. 33 of MRID 49592401; p. 30 of MRID 49800201). However, the soils for

which matrix effects were assessed in the ECM were reported as Loam and Sandy Loam, not the test soil, sand.

- 9. In the ECM, recovery of fluazifop-p-butyl and fluazifop in soil in acetonitrile:10 mM ammonium acetate buffer at pH 5 (30:70; v:v) was found to be acceptable (>80%) after 7 days of refrigerated storage (4°C; p. 27; Tables 5-6, p. 34 of MRID 49592401). However, the soils for which storage stability was assessed in the ECM were reported as Loam and Sandy Loam, not the test soil, sand.
- 10. The reviewer noted that the raw chromatograms, matrix effect data and storage stability data were not taken from a previously submitted ECM for soil: EPA MRID No. 49193107. Huang, S.-B. 2010. Fluazifop-P-Butyl: GRM044.03A Analytical Method for the Determination of Fluazifop-P-Butyl (R154875; PP5), Fluazifop-P-Acid (R156172) and Compound X (R154719; CGA142110) in Soil Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Analytical Method Amendment. Report No.: GRM044.03A. Task No.: TK0019659. Report prepared, sponsored and submitted by Syngenta Crop Protection, LLC., Greensboro, North Carolina; 74 pages. Final report issued September 27, 2010. This soil method ECM used two loam soils, one sandy loam soil and a sand soil for validation.
- 11. It was reported for the ILV that one batch of thirteen samples required one working day with LC/MS/MS performed overnight (p. 30 of MRID 49800201).


V. References

- U.S. Environmental Protection Agency. 2012. Ecological Effects Test Guidelines, OCSPP 850.6100, Environmental Chemistry Methods and Associated Independent Laboratory Validation. Office of Chemical Safety and Pollution Prevention, Washington, DC. EPA 712-C-001.
- 40 CFR Part 136. Appendix B. Definition and Procedure for the Determination of the Method Detection Limit-Revision 1.11, pp. 317-319.

Attachment 1: Chemical Names and Structures


Fluazifop-P-Butyl (racemic mixture); R117009; CGA128175; PP9; R224237

IUPAC Name:	(R,S)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
	butyl ester
CAS Name:	Not reported
CAS Number:	69806-50-4
SMILES	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)OCCCC)cc2
String:	




Fluazifop (racemic mixture); Fluazifop-P-Acid; R115625; CGA85619; PP6

IUPAC Name:	(R,S)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
CAS Name:	2-[4-[[5-(Trifluoromethyl)-2-pyridinyl]oxy]phenoxy]propanoic acid
CAS Number:	69335-91-7
SMILES	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)O)cc2
String:	




Fluazifop-P-Butyl (R enantiomer); R154875; CGA149108; PP5

IUPAC Name:	(R)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
	butyl ester
	Butyl (R)-2-{4-[5-(trifluoromethyl)-2-pyridyloxy]phenoxy}propionate
CAS Name:	Butyl (2R)-2-[4-[[5-(trifluoromethyl)-2-
	pyridinyl]oxy]phenoxy]propanoate
CAS Number:	79241-46-6
SMILES String:	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)OCCCC)cc2




Fluazifop (R enantiomer); Fluazifop-P-Acid; R156172

IUPAC Name:	(R)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
CAS Name:	Not reported
CAS Number:	83066-88-0
SMILES String:	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)O)cc2



Fluazifop-P-Butyl (S enantiomer); R159618

IUPAC Name:	(S)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
	butyl ester
CAS Name:	Not reported
CAS Number:	Not reported
SMILES String:	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)OCCCC)cc2



Fluazifop (S enantiomer); Fluazifop-P-Acid; R159697

IUPAC Name:	(S)-2-[4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenoxy]-propionic acid
CAS Name:	Not reported
CAS Number:	95977-30-3
SMILES String:	n1cc(C(F)(F)F)ccc1Oc2ccc(OC(C)C(=O)O)cc2

